Longeveron (NASDAQ:LGVN – Get Free Report) and NexImmune (NASDAQ:NEXI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.
Valuation & Earnings
This table compares Longeveron and NexImmune’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Longeveron||$1.22 million||34.18||-$18.83 million||($0.95)||-2.07|
Longeveron has higher revenue and earnings than NexImmune. Longeveron is trading at a lower price-to-earnings ratio than NexImmune, indicating that it is currently the more affordable of the two stocks.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Longeveron has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, NexImmune has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.
Insider and Institutional Ownership
3.8% of Longeveron shares are owned by institutional investors. Comparatively, 26.3% of NexImmune shares are owned by institutional investors. 75.2% of Longeveron shares are owned by company insiders. Comparatively, 20.1% of NexImmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of recent recommendations and price targets for Longeveron and NexImmune, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Longeveron currently has a consensus target price of $12.50, suggesting a potential upside of 534.52%. Given Longeveron’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Longeveron is more favorable than NexImmune.
Longeveron beats NexImmune on 9 of the 13 factors compared between the two stocks.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, an allogeneic medicinal signaling cell therapy product isolated from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.